Human capital firm Paycor (PYCR) priced its IPO at $23/share, above a previous range of $18 to $21. The company raised $425.5M by selling 18.5M shares, according to a statement
Regarding the trend, note that the strongest trend exists on the 100 hour timeframe.The post Ceridian HCM Holding Inc (CDAY): Price Now Near $96.14; Daily Chart Shows An Uptrend...
Russia-focused oil and gas company Zoltav Resources Inc (AIM: ZOL) has seen its shares flare up after reducing full year losses. Revenues rose 2% and its operating loss fell by...
BeiGene of Beijing has been approved to stage a $3 billion IPO on the Shanghai Star Stock Exchange. It will be the first Chinese biopharma to be listed in Shanghai, Hong Kong, and...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Sell | Buy | Strong Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Buy | Strong Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 385.20 | 389.00 | 381.60 | -2.10 | -0.54% | 5.28M | London | |||
| 0.40 | 0.00 | 0.00 | 0.000 | 0.00% | 0.00 | London | |||
| 857.20 | 859.20 | 847.00 | +8.60 | +1.01% | 757.94K | London | |||
| 15.73 | 16.14 | 15.28 | -0.09 | -0.57% | 154.03K | London | |||
| 381.00 | 383.00 | 378.00 | +4.00 | +1.06% | 855.72K | London | |||
| 293.00 | 296.50 | 289.50 | +7.00 | +2.45% | 246.17K | London | |||
| 57.00 | 60.30 | 56.60 | -2.90 | -4.84% | 4.02M | London | |||
| 118.84 | 121.12 | 118.04 | +2.80 | +2.41% | 93.01M | London | |||
| 45.88 | 46.07 | 45.36 | +0.66 | +1.45% | 77.42M | London | |||
| 1,099.00 | 1,107.00 | 1,086.00 | +15.00 | +1.38% | 116.17K | London | |||
| 1,268.00 | 1,278.00 | 1,266.00 | +12.00 | +0.95% | 67.75K | London | |||
| 1.72 | 1.84 | 1.71 | +0.02 | +1.18% | 23.14M | London | |||
| 48.84 | 49.78 | 48.30 | +0.48 | +0.99% | 1.28M | London | |||
| 401.60 | 404.95 | 400.10 | +0.90 | +0.23% | 8.86M | London | |||
| 168.46 | 174.00 | 168.06 | -1.92 | -1.13% | 14.81M | London |
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.